全國服務咨詢熱線：
18438616290
<b id="grzca"><menuitem id="grzca"></menuitem></b>
18438616290
簡要描述：Cinaciguat 329773-35-5Cinaciguat (BAY 58-2667) is the first of a new class of soluble guanylate cyclase (sGC) activators in clinical development for acute decompensated heart failure.
產(chǎn)品型號：abs47027876廠商性質(zhì)：生產(chǎn)廠家更新時間：2026-01-05訪 問 量：745產(chǎn)品分類
Product Category詳細介紹
| 品牌 | absin | CAS | 329773-35-5 |
|---|---|---|---|
| 分子式 | C36H39NO5 | 純度 | 98% |
| 分子量 | 565.7 | 貨號 | abs47027876 |
| 規(guī)格 | 5mg | 供貨周期 | 現(xiàn)貨 |
| 主要用途 | is the first of a new class of soluble g | 應用領域 | 化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合 |
Cinaciguat 329773-35-5
| 產(chǎn)品描述 | |
| 描述 | Cinaciguat (BAY 58-2667) is the first of a new class of soluble guanylate cyclase (sGC) activators in clinical development for acute decompensated heart failure. |
| 純度 | 98% |
| 儲存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 可溶性/溶解性 | 10 mM in DMSO |
| 生物活性 | |
| 靶點 | Guanylate Cyclase |
| In vitro(體外研究) | Cinaciguat (10 μM) significantly enhances intracellular cGMP generation. Cinaciguat does not dose-dependent effects on cell contraction and calcium transients. |
| In vivo(體內(nèi)研究) | Cinaciguat (10 mg/kg/day, p.o.) treatment in diabetic rats does not influence blood glucose levels, but leads to attenuated water intake. Cinaciguat treatment alleviates diabetes mellitus related oxidative stress, protects against DM related alteration of the NO-sGC-cGMP-PKG signalling, and alleviates DM related myocardium hypertrophy and apoptosis. Cinaciguat (1-10-100 nM) induces concentration-dependent relaxations in strips from both WT and apo-sGC mice, but does not have any effect on phasic activity induced by PGF2α in WT or apo-sGC strips. |
| 參考文獻 | |
| 參考文獻 |
|
| 研究領域 | |
| 研究領域 | Signal TransductionProtein PhosphorylationSer / Thr KinasesOther Kinases Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產(chǎn)品咨詢
地址：上海市浦東新區(qū)新浩路58號申江科創(chuàng)園18棟
郵箱：
傳真：